Simultaneous spectrophotometric determination of compounds: Application to an anti-diabetic formulation of Teneligliptin and Metformin

Teneligliptin and Metformin are antidiabetic drugs. Teneligliptin is a novel oral DPP-4 inhibitor classified as peptidomimetic and approved in Japan in September 2012 for the management of Type 2 diabetes mellitus. Type 2 diabetes mellitus is a chronic progressive disease and involves multiple systems. Metformin is biguanide derivative which decreases hepatic glucose production as well as intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Teneligliptin has been systematically evaluated in as monotherapy with diet and exercise and in combination with metformin, glimepiride, pioglitazone, and insulin in short-term (12 weeks) and long-term (52 weeks) studies. In the present study three new spectrophotometric methods such as Dual wavelength method (Method A), Graphical absorbance ratio method (Method B) and First derivative (Method C) method were proposed for the simultaneous determination of Teneligliptin and Metformin tablets using hydrochloric acid. Linearity was observed 1–30 μg/ml and 1–80 μg/ml in both Method A and Method B and 1–30 μg/ml and 1–100 μg/ml in Method C for Metformin and Teneligliptin respectively. The methods were validated as per ICH guidelines and applied for the simultaneous determination of Teneligliptin and Metformin tablets.